1. Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: review and pooled analysis of observational studies;Abraham;Leuk. Res.,2017
2. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial);Angelucci;Eur. J. Haematol.,2014
3. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and Int-1-risk myelodysplastic syndromes (MDS): Outcomes from the randomized, double-blind Telesto study. Blood 132;Angelucci;abstract,2018
4. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome;Badawi;Adv. Hematol.,2010
5. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life;Balducci;Cancer,2006